drugset
drugset / Trial / NCT05684705

Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100

NCT05684705 ↗

Phase 1 Completed 35 enrolled BioVersys AG CW-Research and Management GmbH · collab
NaSingle-groupOpen-labelTreatment

Summary

Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100

Timeline

Start
2023-09-01
Primary completion
2024-10-30
Completion
2024-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifabutin Small molecule — Intravenous

Indications

bacterial infectious disease